RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.
Date
2017-02-27
RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.
(if you want to view the body of article, click on the bottom link)
http://www.prnewswire.com/news-releases/regenerx-licensee-receives-fda-permission-to-conduct-a-phase-3-trial-of-rgn-137-for-epidermolysis-bullosa-in-us-300413786.html
(if you want to view the body of article, click on the bottom link)
http://www.prnewswire.com/news-releases/regenerx-licensee-receives-fda-permission-to-conduct-a-phase-3-trial-of-rgn-137-for-epidermolysis-bullosa-in-us-300413786.html